drugset / Trial / NCT00004122
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
Treatment
Summary
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells. Combining these therapies may be an effective treatment for bladder cancer. PURPOSE: Phase II trial to study the effectiveness of BCG plus interferon alfa 2b in treating patients who have bladder cancer.
Timeline
- Start
- 1999-07
- Primary completion
- 2001-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCG vaccine | Vaccine | — | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Intravenous |